Status: Not yet recruiting
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
The primary objective of the study is to compare the changes in serum ALT level among patients with non-alcoholic steatohepatitis (NASH) following 3-month treatment of 800 mg SNP-610 or the placebo. The secondary objectives will be to compare the changes in liver fat fraction, other liver function tests, cytokeratin-18 (CK-18) fragment level and adverse event / serious adverse event rates among the interventional and placebo arms.
Participants needed: 80
Trial details
Phase: Phase 2Age: 20+Biological sex: AllType: InterventionalSponsor: Sinew Pharma Inc.Updated: Mar 18, 2026
Eligibility criteria
Age ≥ 20 years [+6]
Confirmed cirrhosis or suspicion of cirrhosis [+14]